 

Active Ingredient: Benzonatate 

 

Dosage Form; Route: Capsule; oral 

 

Recommended Studies: 

 

Benzonatate capsules, 100 mg, 150 mg, and 200 mg, may be considered for waiver of in vivo 
bioequivalence (BE) testing pursuant to 21 C.F.R. 320.22(c), provided the in vitro dissolution 
profiles of the test benzonatate capsules, 100 mg, 150 mg, and 200 mg, and the reference listed 
drugs (RLDs) are comparable. 

_____________________________________________________________________________ 

 

Analytes to measure (in appropriate biological fluid): Not applicable (N/A) 

 

Bioequivalence based on (90% CI): N/A 

 

Waiver request of in vivo testing: 100 mg, 150 mg, and 200 mg oral capsules pursuant to 21 
CFR 320.22 (c). 

 

Dissolution test method and sampling times: The dissolution information for this drug 
product can be found on the FDA-Recommended Dissolution Methods Web site, available to the 
public at the following location: http://www.accessdata.fda.gov/scripts/cder/dissolution/. 
Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and 
reference products. Specifications will be determined upon review of the abbreviated new drug 
application (ANDA). 


